How much revenue does Mercury Laboratories make?

Mercury Laboratories reported 751.01 million INR in revenue for fiscal year 2025, down 0.6% from 755.59 million INR in fiscal year 2024. In Q3 2026 revenue was 183.50 million INR.

What companies are similar to Mercury Laboratories?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Gujarat Inject (Kerala) Ltd (GUJINJEC.BO), Parnax Lab Limited (PARNAXLAB.BO), Concord Drugs Limited (CONCORD.BO), Shelter Pharma Limited (SHELTER.BO).

Mercury Laboratories Limited (MERCURYLAB.BO) Stock

About Mercury Laboratories Limited

Mercury Laboratories Limited engages in manufacturing, selling, exporting, and dealing in various pharmaceutical drugs and medicines for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system,...

At a glance

Mercury Laboratories reported revenue of 751.01 million INR for fiscal year 2025, down 0.6% from fiscal year 2024, and net income of 31.45 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 183.50 million INR, down 6.2% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.